• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing
  3. / Consumer Staples

Joel Greenblatt's Top 'Magic Formula' Stocks

These three holdings offer consistent earnings growth and impressive returns on invested capital.
By MEENA KRISHNAMSETTY Sep 12, 2012 | 03:30 PM EDT
Stocks quotes in this article: UTHR, TPX, NUS

Joel Greenblatt, the founder of Gotham Asset Management, is widely known for his "magic formula" investment approach. This strategy searches for companies that offer a combination of a high return on invested capital and a high earnings yield. Like many other value investors, Greenblatt seeks stocks whose intrinsic value is substantially higher than the current price level.

Looking at the sector composition of Greenblatt's portfolio, the services and technology sectors are the most heavily weighted, composing 21.9% and 27.3% of his total holdings. To identify what companies Greenblatt currently views as "heavily undervalued," we must look at stocks that exhibited large swings in portfolio value between the first and second quarters of this year.

United Therapeutics (UTHR) accounts for 1.2% of Greenblatt's holdings and is the second-largest investment in Gotham Asset Management's total 13F portfolio. From the first to the second quarter of 2012, Greenblatt doubled his position in the biotechnology company, which is focused on developing products for patients who have life-threatening conditions.

As expected, United Therapeutics has been a strong performer among biotech companies. The company has experienced seven years of growth in cash profits (three years GAAP) and has been on Deloitte's list of fastest-growing companies for 11 years running. It also has the second-highest revenue per employee among its peers. It is likely that Greenblatt sees value in this biotech because of its consistent historical performance, as United Therapeutics is among the leaders in all three of its market segments. Additionally, the company has forecasted that it will hit sales of $2 billion in 2013, stemming from its late-stage pipeline of products.

From a magic-formula perspective, United Therapeutics' return on invested capital has increased every year since 2007, and it was 18.69% last year. The stock has returned nearly 16% year to date and is trading at 11.6x earnings. Moreover, the company's insiders have been particularly bullish, most notably CEO A. Martine Rothblatt. Here's a full list of Rothblatt's transactions.

Greenblatt's second-quarter 13F filings also reveal a large position in the mattress and pillow manufacturer Tempur-Pedic International (TPX). The hedge fund manager has taken an $8 million position in Tempur-Pedic; the stock accounts for 0.58% of his total portfolio's holdings.

Between April and July of this year, Tempur-Pedic released guidance figures that were below analysts' estimates. This caused the company's stock price to tumble from the $87 range in April to a low of $23 in June. During this selloff, we suspect that Greenblatt kept his emotions in check and remembered that Tempur-Pedic was still the leader in the non-spring and premium mattress market segments, in addition to being among the industry leaders in operating margin and cash flows.

Over the past three years, the company has more than doubled its return on invested capital, from 17.68% in 2009 to 38.23% in 2011. Since reporting his holdings at the end of June, Greenblatt has seen Tempur-Pedic's stock price recover by nearly 40%. Since the stock still trades at 10.4x earnings, which is far below the industry average P/E of 23.1, there looks to be more value here.

Nu Skin Enterprises (NUS) accounts for 0.40% of Greenblatt's portfolio. Greenblatt increased his position in the anti-aging personal care developer by 581% in the second quarter of 2012. Year to date, the stock has been volatile, as investors seem unsure about the company's potential. From December 2011 to March of this year, the company's stock price performed particularly well, jumping by more than 20% over this time period.

When the company raised its 2012 guidance by a less than expected amount in April, however, investors weren't impressed, and they pushed prices down 30% to the $40 mark by early May. We suspect that Greenblatt saw a bargain-bin opportunity in this particular selloff, as Nu Skin was still the same company that had increased revenue every year since 2007 and had projected 2012 revenue of $2.03 billion, up from the $1.74 billion it reported in 2011.

In addition to this growth, the company's operating and net margins have grown quite significantly over the past half-decade, while earnings have improved every year since 2007. Moreover, Nu Skin has increased its return on invested capital substantially over this time period, from 6.65% in 2006 to 22.84% in 2011.

It appears that a bit of the market's uncertainty over this stock is a result of a report from Citron Research about Nu Skin's alleged unfair business practices. The report stated that the personal-care products maker is operating an illegal multi-level marketing scheme in China. Citron believes that Nu Skin's direct-selling business in China is actually a pyramid scheme that is illegal under Chinese law.

Because of concerns over these accusations, Nu Skin is trading at a P/E ratio of 13.7x, below its five-year (17.7x) and 10-year (20.3x) historical averages. The company's earnings are also valued below those of competitors such as Avon Products (AVP) and Estee Lauder (EL), which sport P/E ratios of 27.4 and 28.3 respectively. When growth is factored into the equation, we can see that Nu Skin has a price/earnings-to-growth ratio of 0.87; typically any figure below 1.0 signals undervaluation.

To recap, Joel Greenblatt is heavily invested in these three stocks because of their consistent earnings growth and impressive returns on invested capital. Because of these two factors, each company has positioned itself to see moderate price appreciation in the next 12 to 16 months.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

This article is written by Mike Pate and edited by Meena Krishnamsetty. They don't own shares in any of the stocks mentioned in this article.

TAGS: Investing | U.S. Equity | Consumer Staples

More from Consumer Staples

I'm Intrigued as Kellogg Splits Into 3: Here's the Play

Stephen Guilfoyle
Jun 21, 2022 10:15 AM EDT

The company, despite a nice looking first quarter, has not been in the greatest shape fundamentally.

Any Bounce in This Nasty Bear Market Should Be Viewed With Caution

Bob Byrne
May 11, 2022 8:30 AM EDT

For now, any rebound is a short-term trading opportunity and nothing more.

3 Name-Brand Stocks That Traders Might Take a Stab at in This Rotten Market

Bob Byrne
May 9, 2022 8:30 AM EDT

Rather than try to catch falling knives, traders should give a look at Merck, IBM and Procter & Gamble.

Strange Options Moves on Staples ETF Sparks a Trade Idea

Mark Sebastian
May 4, 2022 2:25 PM EDT

Here's how I would play the XLP right now.

Ketchup? Check. Jelly? Check. Beer? Of Course. Let's Go Get Some Staples

Ed Ponsi
Apr 28, 2022 10:30 AM EDT

Names like J.M. Smucker and Kraft-Heinz may seem dull, but they provided needed stability in this kind of market. Let me show you why it's time to get back to the basics.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 12:10 AM EDT PAUL PRICE

    More Insider Buying in American Woodmark (AMWD)

    American Woodmark , which I've discussed here fr...
  • 08:55 AM EDT JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    The 10 personality traits of successful traders an...
  • 12:08 PM EDT STEPHEN GUILFOYLE

    Stocks Under $10

    As a Portfolio Name Agrees to a Merger, Here's Our...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2022 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login